## Chiara Pavanello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/427385/publications.pdf

Version: 2024-02-01

24 papers 661 citations

567281 15 h-index 23 g-index

25 all docs

25 docs citations

25 times ranked

1001 citing authors

#	Article	IF	CITATIONS
1	The HDL mimetic CERâ€001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency. Journal of Internal Medicine, 2022, 291, 364-370.	6.0	11
2	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
3	Plasma FA composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans. Journal of Lipid Research, 2022, 63, 100232.	4.2	4
4	Two novel variants in the lecithin:cholesterol acyltransferase gene resulted in classic LCAT deficiency. Atherosclerosis Plus, 2022, , .	0.7	0
5	Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos). Journal of Lipid Research, 2021, 62, 100065.	4.2	5
6	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red) Tj ETQc	0 <b>4.0</b> rgB <sup>-</sup>	Γ/ <b>@</b> verlock 10
7	Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 463-468.	2.5	13
8	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. Atherosclerosis, 2020, 312, 72-78.	0.8	25
9	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	3.2	21
10	The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL. PLoS ONE, 2020, 15, e0229322.	2.5	4
11	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. Atherosclerosis, 2020, 297, 8-15.	0.8	12
12	Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. Journal of Lipid Research, 2020, 61, 1784-1788.	4.2	19
13	Familial LCAT deficiency and cardiovascular disease: the game is not over. A case of dramatic multivessel atherosclerosis. Minerva Medica, 2020, , .	0.9	1
14	Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutrition Journal, 2019, 18, 13.	3.4	37
15	Autosomal Recessive Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 279-288.	2.8	38
16	Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. European Journal of Nutrition, 2018, 57, 499-511.	3.9	49
17	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Advances in Therapy, 2017, 34, 1200-1210.	2.9	56
18	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. Journal of Lipid Research, 2017, 58, 994-1001.	4.2	18

#	Article	IF	CITATIONS
19	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
20	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
21	Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial. Journal of Functional Foods, 2017, 37, 8-15.	3.4	22
22	High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis. Endocrinology and Metabolism, 2016, 31, 223.	3.0	35
23	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. Journal of Clinical Lipidology, 2015, 9, 226-233.	1.5	22
24	Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. Journal of Clinical Lipidology, 2014, 8, 61-68.	1.5	74